Ind-Swift Laboratories Limited Stock Price Today (NSE: INDSWFTLAB)
Fundamental Score
Ind-Swift Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ind-Swift Laboratories Limited share price today is ₹368.20, down 10.15% on NSE/BSE as of 30 October 2026. Ind-Swift Laboratories Limited (INDSWFTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.20K (Cr). The 52-week high for INDSWFTLAB share price is ₹426.60 and the 52-week low is ₹87.15. At a P/E ratio of 53.99x, INDSWFTLAB is currently trading above its industry average P/E of 34.89x. 0
Ind-Swift Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Ind-Swift Laboratories Limited share price chart: -1.28% return over the past month. 52-week high ₹426.60, 52-week low ₹87.15.
Ind-Swift Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹417.90 | ₹426.60 | ₹352.35 | ₹368.20 | 36.08L (Cr) | |
| ₹381.00 | ₹425.00 | ₹373.05 | ₹409.80 | 35.39L (Cr) | |
| ₹376.20 | ₹382.00 | ₹363.00 | ₹378.95 | 5.90L (Cr) | |
| ₹335.00 | ₹376.00 | ₹335.00 | ₹368.80 | 8.51L (Cr) | |
| ₹320.00 | ₹344.20 | ₹316.00 | ₹337.05 | 4.15L (Cr) | |
| ₹345.00 | ₹348.70 | ₹321.15 | ₹327.45 | 6.58L (Cr) | |
| ₹337.00 | ₹350.55 | ₹336.00 | ₹345.35 | 2.70L (Cr) | |
| ₹353.00 | ₹366.00 | ₹336.80 | ₹342.50 | 6.44L (Cr) | |
| ₹358.85 | ₹364.00 | ₹350.00 | ₹351.90 | 2.31L (Cr) | |
| ₹358.00 | ₹370.00 | ₹352.00 | ₹359.25 | 3.10L (Cr) |
Ind-Swift Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹388.60 | ₹426.60 | ₹316.00 | ₹368.20 | -5.25% | |
| ₹368.45 | ₹424.75 | ₹320.20 | ₹388.75 | +5.51% | |
| ₹224.27 | ₹373.72 | ₹222.20 | ₹364.87 | +62.69% | |
| ₹203.95 | ₹248.45 | ₹197.10 | ₹224.27 | +9.96% | |
| ₹154.00 | ₹211.00 | ₹152.80 | ₹203.53 | +32.16% | |
| ₹138.11 | ₹161.00 | ₹129.31 | ₹152.11 | +10.14% | |
| ₹135.00 | ₹156.80 | ₹127.30 | ₹137.54 | +1.88% | |
| ₹138.00 | ₹151.51 | ₹126.00 | ₹131.43 | -4.76% | |
| ₹112.90 | ₹151.98 | ₹106.23 | ₹145.33 | +28.72% | |
| ₹89.24 | ₹117.80 | ₹87.25 | ₹113.41 | +27.08% | |
| ₹97.00 | ₹99.50 | ₹87.15 | ₹88.15 | -9.12% | |
| ₹102.71 | ₹106.50 | ₹93.00 | ₹97.48 | -5.09% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ind-Swift Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ind-Swift Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDSWFTLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (19.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (25.35%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (66.22% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (77.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (35.91x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.83)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.83%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 53.99x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-5.62% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-93.03 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 8.62%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ind-Swift Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ind-Swift Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ind-Swift Laboratories LimitedInd-Swift Labor...Selected✓ INDSWFTLAB • 532305 | 50.4/100 | ₹368.20₹368 | ₹3197.32₹3197.32 | 53.99Average 54.0 Average | 0.00%Poor 0.00% Poor | 3.83%Poor 3.83% Poor | 0.01Excellent 0.0 Excellent | 77.68%Excellent 77.68% Excellent | -5.62%Poor -5.62% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Ind-Swift Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for INDSWFTLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹71.24 | ₹108.57 | 1.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ind-Swift Laboratories Limited Quarterly Performance
Latest quarterly metrics for INDSWFTLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
25.35%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.35%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-5.62%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
77.68%
Compounded annual net profit growth over 5 years
Ind-Swift Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDSWFTLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ind-Swift Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Ind-Swift Laboratories Limited (INDSWFTLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Ind-Swift Laboratories Limited
About INDSWFTLAB (Ind-Swift Laboratories Limited)
Ind Swift Laboratories Ltd is a dynamic pharmaceutical entity carving its niche in the global healthcare landscape. With a steadfast commitment to innovation and quality, the compa...ny dedicates its resources to the research, development, and production of a diverse portfolio of pharmaceutical products. Its activities are deeply rooted in scientific rigor, with a focus on creating effective and accessible medications for a range of therapeutic needs. By combining advanced technologies and skilled personnel, Ind Swift Laboratories strives to address pressing health challenges and improve patient outcomes worldwide. The company stands as a testament to the power of dedicated pharmaceutical research in improving global health. The core business of Ind Swift Laboratories revolves around the creation of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished formulations, contributing to a comprehensive approach to drug development and manufacturing. The company strategically markets these products both domestically and internationally, reaching healthcare providers and patients across different regions. They have a strong emphasis on the manufacturing process, as the creation of APIs requires the utmost control. They're committed to high quality ingredients to ensure the safety and efficacy of its medicinal products. Ind Swift Laboratories is not just producing pharmaceuticals, but rather, is actively contributing to global healthcare solutions through its expanded reach and market strategy. Ind Swift Laboratories' dedication goes beyond simple manufacturing; they operate as an innovative force, pushing the boundaries of pharmaceutical science. This commitment is evident in its expanding portfolio of APIs, which caters to a broad spectrum of therapeutic areas. This includes treatments for cardiovascular conditions, diabetes, and a host of other ailments, demonstrating its commitment to addressing a wide range of health concerns. Through tireless effort and a focus on continuous improvement, Ind Swift Laboratories seeks to develop novel solutions that contribute to a healthier future. This dedication to improving the lives of individuals through innovative pharmaceuticals is the driving force behind Ind Swift Laboratories' growth and success.
Company Details
Key Leadership
INDSWFTLAB Share Price: Frequently Asked Questions
What is the current share price of Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited (INDSWFTLAB) trades at ₹368.20 on NSE and BSE. Market cap ₹3.20K (Cr). Educational data only.
What is the P/E ratio of Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited has a P/E of 53.99x vs industry average 34.89x.
What is the Bull Run score for Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited has a Bull Run score of 50.4/100 based on 25+ financial parameters.
Does Ind-Swift Laboratories Limited pay dividends?
Ind-Swift Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited has debt-to-equity of 0.01.
Is Ind-Swift Laboratories Limited a good investment?
Bull Run gives Ind-Swift Laboratories Limited a score of 50.4/100. This is not investment advice — consult a SEBI-registered advisor.